Molecular Breast Imaging: Clear Look Beyond Mammography, MRI, Ultrasound
Dilon Technologies, Inc., a leader in molecular breast imaging, announced today that leading physicians will present studies at the annual meeting of the Radiological Society of North America (RSNA) that demonstrate Breast Specific Gamma Imaging (BSGI) goes beyond mammography, MRI and ultrasound, and is emerging as a cost-effective adjunct imaging modality for breast cancer diagnostics.
Researchers are advancing the early detection of breast cancer, especially in difficult-to-diagnose patients, using this molecular breast imaging technique.
"This research will demonstrate compelling evidence that BSGI is paving the way to the effective diagnosis of breast cancer," said Bob Moussa, President and CEO of Dilon Technologies. "BSGI provides critical diagnostic information for physicians to diagnose and treat patients. In these cases you will see BSGI performing as well as, if not better than, mammography, MRI and ultrasound."
BSGI is an adjunctive molecular breast imaging technique to mammography that can see lesions independent of tissue density and discover early stage cancers. With BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body.
Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal, healthy cells and generally appear as "hot spots" on the BSGI image.
The Dilon 6800 Gamma Camera is a high-resolution, small field-of-view gamma camera, optimized to perform BSGI.